Le Vésinet, France

Julien Caumartin

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 18(Granted Patents)


Location History:

  • Le Vesinet, FR (2018 - 2021)
  • Le Vésinet, FR (2021 - 2023)

Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Julien Caumartin

Introduction

Julien Caumartin is a notable inventor based in Le Vésinet, France. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 8 patents, Caumartin's work focuses on advancing therapeutic approaches against specific human leukocyte antigens.

Latest Patents

Among his latest patents, Caumartin has developed chimeric antigen receptors (CAR) that target multiple isoforms of human leukocyte antigen-G (HLA-G). This invention specifically addresses CARs that are effective against both β2M-free and β2M-associated immunosuppressive isoforms. Additionally, he has created anti-HLA-G specific antibodies, which are directed against the HLA-G protein. These antibodies are raised against an immunogenic peptide derived from the α3 domain of the HLA-G protein, showcasing his innovative approach to immunotherapy.

Career Highlights

Throughout his career, Julien Caumartin has worked with various companies, including Invectys and Invectys Sa. His work in these organizations has allowed him to further develop his research and contribute to advancements in the field of immunology.

Collaborations

Caumartin has collaborated with notable colleagues such as Maria Loustau and Pierre Langlade Demoyen. These partnerships have likely enriched his research and contributed to the success of his innovative projects.

Conclusion

Julien Caumartin's contributions to immunology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in therapeutic approaches against immunosuppressive conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…